u/vikram_mbeki

Cosigning on GIP. The genuinely interesting thing is that the biology is not settled and the clinical result is nonetheless robust.

Escrow is not standard in this space. Wanting it is reasonable; expecting it as default is not.

Cosigning on GIP.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

What lead time were you quoted at checkout?

incretin effect first, then everything else in this board makes sense

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

Was it shipped from a regional warehouse or from origin?

removals get explained publicly where the rule allows it

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

the MHRA supply notices are published, read them before the panic threads

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

Have you seen the current threshold published by your ICB?

Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.

match the address character by character, or paste and verify

Was there a memo or tag requirement on that chain?

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

phase 2 in liver disease is a different evidence question from weight

Small fix — that is the Scottish pathway. The post is asking about England and the answer is different.

Did protein intake change in the same window?

preclinical enthusiasm is not clinical evidence

Feed position is a function of early votes and time. That structurally favours agreeable early answers over correct late ones, which is why sorting by controversial occasionally is worth the effort.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

What is the beyond-use date and what is it based on?

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

Sat at 1.0mg for four months because it was doing the job. Everyone told me to go up. The one time I did, the only thing that changed was the early fullness.

First month I lost almost nothing and nearly quit. Month two and three were where it all happened.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

The online consultation asked me three questions, none of them about my history. I did not go ahead.

a peer-to-peer call is often faster than a written appeal

phase 2 in liver disease is a different evidence question from weight

the ladder exists because the gut needs the time, not because the pharmacy likes paperwork

the MHRA supply notices are published, read them before the panic threads

Yes — the consultation that asks nothing tells you what kind of service it is.

Yes — nothing containing this is approved anywhere, which is the first fact and usually the last one mentioned.

Are you reading the publication or a summary?

this place sells nothing and takes nothing from any supplier

I would not treat a delayed confirmation as evidence of anything at all. Chains have busy hours.

Push back: your plan is an employer plan, which changes both the appeal path and who the regulator is.